Effect of a Proposed Cav1.3 Inhibitor in Primary Aldosteronism

Summary

The goal of this pilot, open-label prospective study is to evaluate if the effect of calcium channel blockade on plasma aldosterone levels in people with primary aldosteronism (PA) is due primarily to Cav1.3 blockade. This will be tested by treating participants who have PA with both cinnarizine (Cav1.3 blocker) and nifedipine (Cav1.2 blocker) and evaluating effect on aldosterone levels and blood pressure over a two week course of treatment.

Timeline

Start

2023-04-24

Primary completion

2023-09-01

Completion

2023-09-06

Publications

• Ng E, Lee YN, Taylor A, Shaheen F, Azizan E, Drake WM, Brown MJ. Evaluation of Aldosterone Suppression by Cinnarizine, a Putative Cav1.3 Inhibitor. J Clin Endocrinol Metab. 2025 Sep 16;110(10):2752-2761. doi: 10.1210/clinem/dgaf081.

Drugs

Indications